← Back to Patent Explorer
US4851233A Expired / Lapsed US ⏱️ 0.0 years remaining

Sustained release formulations

Assignee: Warner Lambert Co LLC
•
Filing: 1986-10-06
•
Granted: 1989-07-25
•
Expires: 2006-10-06
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A new drug delivery system, which gives sustained release properties is made by combining certain cellulosic polymers with cellulose in a binder system.

Inventors

  • 👤 Sadath U. Khan
  • 👤 Reginald Phillips

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-30 09:04
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61K31/21; A61K31/215; A61K31/235; A61K31/24; A61K31/245; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/205; A61K9/2054

Claims Analysis

Total Claims: 4
Claim 1
Independent Claim 92 words
A compressed tablet binder system mixture consisting essentially of: (a) about 60-90 wt % of procainamide hydrochloride or sodium meclofenamate, (b) about 5-20 wt % of a Type "H" hydroxy ethyl cellulose, and (c) about 5-15 wt % of microcrystalline cellulose, which is further coated by the hydroxy ethyl cellulose; said hydroxy ethyl cellulose rapidly hydrating to a transient gel state which persists long enough to provide a sustained dissolution with drug release occurring via a slow diffusion and matrix erosion; said tablet being completely disintegrated at the end of drug dissolution.
Claim 2
Dependent Claim 92 words
A compressed tablet binder system mixture consisting essentially of: (a) about 60-90 wt % of procainamide hydrochloride or sodium meclofenamate, (b) about 5-20 wt % of a Type "H" hydroxy ethyl cellulose, and (c) about 5-15 wt % of microcrystalline cellulose, which is further coated by the hydroxy ethyl cellulose; said hydroxy ethyl cellulose rapidly hydrating to a transient gel state which persists long enough to provide a sustained dissolution with drug release occurring via a slow diffusion and matrix erosion; said tablet being completely disintegrated at the end of drug dissolution.
Claim 3
Dependent Claim 10 words
The composition of claim 1 wherein (a) comprises procainamide hydrochloride.
Claim 4
Dependent Claim 10 words
The composition of claim 1 wherein (a) comprises sodium meclofenamate.

References Cited (Backward Citations)

US4309404A Cited
US4252786A Cited
US4369172A Cited
US4525345A Cited
US4389393A Cited
US4389393B1 Cited
US4461759A Cited
US4505890A Cited
US4555399A Cited
US4610870A Cited
US4792452A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1992-07-24 1993-01-23 1993-07-25 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1996-07-24 1997-01-23 1997-07-25 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2000-07-24 2001-01-23 2001-07-25 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag